Další formáty:
BibTeX
LaTeX
RIS
@proceedings{58287, author = {Slabý, Ondřej and Pokorná, Petra and Pálová, Hana and Kýr, Michal and Múdry, Peter and Štěrba, Jaroslav}, booktitle = {2023 ASCO Annual Meeting I}, doi = {http://dx.doi.org/10.1200/JCO.2023.41.16_suppl.10035}, keywords = {high-risk/refractory pediatric solid tumors; genomic profiling; individual therapeutic planning}, language = {eng}, title = {Comprehensive genomic profiling and individual therapeutic planning in high-risk/refractory pediatric solid tumors: A single-center real-world study.}, url = {https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10035}, year = {2023} }
TY - CONF ID - 58287 AU - Slabý, Ondřej - Pokorná, Petra - Pálová, Hana - Kýr, Michal - Múdry, Peter - Štěrba, Jaroslav PY - 2023 TI - Comprehensive genomic profiling and individual therapeutic planning in high-risk/refractory pediatric solid tumors: A single-center real-world study. KW - high-risk/refractory pediatric solid tumors KW - genomic profiling KW - individual therapeutic planning UR - https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.10035 N2 - gt; 10 mut/Mb). Lymphomas and CNS tumors showed the highest rate of patients with therapeutically actionable findings (60% and 56%, respectively), followed by neuroblastomas (36%), sarcomas (25%), and other solid tumors (23%). All results and individual treatment plans were discussed and approved at multidisciplinary molecular tumor boards. Conclusions: Precision medicine in pediatric oncology has rapidly developed over the last decade and resulted in new therapeutic options based on molecular biomarkers and increased our understanding of the complexity of pediatric malignancies. ER -
SLABÝ, Ondřej, Petra POKORNÁ, Hana PÁLOVÁ, Michal KÝR, Peter MÚDRY a Jaroslav ŠTĚRBA. Comprehensive genomic profiling and individual therapeutic planning in high-risk/refractory pediatric solid tumors: A single-center real-world study. In \textit{2023 ASCO Annual Meeting I}. 2023. ISSN~0732-183X. Dostupné z: https://dx.doi.org/10.1200/JCO.2023.41.16\_{}suppl.10035.
|